ES2843952T3 - Composiciones para tratar el insomnio - Google Patents
Composiciones para tratar el insomnio Download PDFInfo
- Publication number
- ES2843952T3 ES2843952T3 ES15851934T ES15851934T ES2843952T3 ES 2843952 T3 ES2843952 T3 ES 2843952T3 ES 15851934 T ES15851934 T ES 15851934T ES 15851934 T ES15851934 T ES 15851934T ES 2843952 T3 ES2843952 T3 ES 2843952T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- dose
- dosage form
- daily dose
- mean
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title claims abstract description 88
- 206010022437 insomnia Diseases 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title description 37
- 229940126062 Compound A Drugs 0.000 claims abstract description 246
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims abstract description 246
- 238000000034 method Methods 0.000 claims abstract description 49
- MUGXRYIUWFITCP-PGRDOPGGSA-N (1r,2s)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-n-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide Chemical compound CC1=NC(C)=NC=C1OC[C@]1(C=2C=C(F)C=CC=2)[C@H](C(=O)NC=2N=CC(F)=CC=2)C1 MUGXRYIUWFITCP-PGRDOPGGSA-N 0.000 claims abstract description 4
- 239000002552 dosage form Substances 0.000 claims description 99
- 238000004090 dissolution Methods 0.000 claims description 44
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 40
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 29
- 239000006186 oral dosage form Substances 0.000 claims description 22
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 12
- 238000007922 dissolution test Methods 0.000 claims description 11
- 239000012738 dissolution medium Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 7
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 7
- 229940068968 polysorbate 80 Drugs 0.000 claims description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000000902 placebo Substances 0.000 description 65
- 229940068196 placebo Drugs 0.000 description 65
- 206010041349 Somnolence Diseases 0.000 description 54
- 230000036470 plasma concentration Effects 0.000 description 53
- 230000007958 sleep Effects 0.000 description 53
- 238000011282 treatment Methods 0.000 description 43
- 230000008859 change Effects 0.000 description 42
- 208000032140 Sleepiness Diseases 0.000 description 41
- 230000037321 sleepiness Effects 0.000 description 41
- 239000002775 capsule Substances 0.000 description 37
- 238000012360 testing method Methods 0.000 description 34
- 239000003826 tablet Substances 0.000 description 31
- 230000000694 effects Effects 0.000 description 26
- 239000003814 drug Substances 0.000 description 23
- 229940079593 drug Drugs 0.000 description 21
- 238000009472 formulation Methods 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 18
- 239000000306 component Substances 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 13
- 239000008187 granular material Substances 0.000 description 13
- 102000002512 Orexin Human genes 0.000 description 12
- 108060005714 orexin Proteins 0.000 description 12
- 230000002618 waking effect Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 10
- 229960001475 zolpidem Drugs 0.000 description 10
- -1 (2,4-dimethylpyrimidin-5-yl) oxy Chemical group 0.000 description 9
- 239000008186 active pharmaceutical agent Substances 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000007916 tablet composition Substances 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000008030 elimination Effects 0.000 description 7
- 238000003379 elimination reaction Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000007963 capsule composition Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 206010062519 Poor quality sleep Diseases 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 229960003943 hypromellose Drugs 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 230000004622 sleep time Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Chemical class 0.000 description 4
- 230000036626 alertness Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 239000001863 hydroxypropyl cellulose Chemical class 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000003326 hypnotic agent Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- OFNHNCAUVYOTPM-IIIOAANCSA-N orexin-a Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N2)[C@@H](C)O)=O)CSSC1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CNC=N1 OFNHNCAUVYOTPM-IIIOAANCSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000004461 rapid eye movement Effects 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- 108050000742 Orexin Receptor Proteins 0.000 description 3
- 102000008834 Orexin receptor Human genes 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- OHOWSYIKESXDMN-WMQZXSDYSA-N orexin-b Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)C1=CNC=N1 OHOWSYIKESXDMN-WMQZXSDYSA-N 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 208000020685 sleep-wake disease Diseases 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000007580 dry-mixing Methods 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000008452 non REM sleep Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000005426 pharmaceutical component Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000004202 respiratory function Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 230000004620 sleep latency Effects 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000021500 Breathing-related sleep disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 101000986786 Homo sapiens Orexin/Hypocretin receptor type 1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 108050001089 Orexin receptor 2 Proteins 0.000 description 1
- 229940123730 Orexin receptor antagonist Drugs 0.000 description 1
- 102100028141 Orexin/Hypocretin receptor type 1 Human genes 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000006199 Parasomnias Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000013398 bayesian method Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000013498 data listing Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003168 generic drug Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000004599 slow eye movement Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067443P | 2014-10-23 | 2014-10-23 | |
| PCT/JP2015/080304 WO2016063995A1 (en) | 2014-10-23 | 2015-10-21 | Compositions and methods for treating insomnia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2843952T3 true ES2843952T3 (es) | 2021-07-21 |
Family
ID=55761025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15851934T Active ES2843952T3 (es) | 2014-10-23 | 2015-10-21 | Composiciones para tratar el insomnio |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10188652B2 (enExample) |
| EP (1) | EP3209298B1 (enExample) |
| JP (1) | JP6659681B2 (enExample) |
| KR (1) | KR102444608B1 (enExample) |
| CN (1) | CN107810006B (enExample) |
| AU (1) | AU2015336463B2 (enExample) |
| BR (1) | BR112017007063A2 (enExample) |
| CA (1) | CA2964504C (enExample) |
| ES (1) | ES2843952T3 (enExample) |
| IL (1) | IL251759B (enExample) |
| MX (1) | MX376164B (enExample) |
| RU (1) | RU2703297C2 (enExample) |
| SG (2) | SG11201703064WA (enExample) |
| WO (1) | WO2016063995A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6659681B2 (ja) | 2014-10-23 | 2020-03-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 不眠症を治療するための組成物および方法 |
| RU2763493C2 (ru) * | 2016-05-12 | 2021-12-29 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Способы лечения расстройств циркадного ритма сна |
| CN109789141B (zh) * | 2016-08-10 | 2022-08-26 | 豪夫迈·罗氏有限公司 | 包含Akt蛋白激酶抑制剂的药物组合物 |
| JP7179049B2 (ja) * | 2017-08-01 | 2022-11-28 | ベルゲン ファーマシューティカル、 エルエルシー | オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
| KR20210124188A (ko) | 2018-11-21 | 2021-10-14 | 트루모 파마슈티칼스, 인크. | 정제된 형태의 로페콕시브, 제조 및 사용 방법 |
| MX2021016090A (es) * | 2019-06-26 | 2022-02-03 | Eisai R&D Man Co Ltd | Lemborexant para el tratamiento de problemas del sueño. |
| WO2020263253A1 (en) * | 2019-06-26 | 2020-12-30 | Moline Margaret | Lemborexant for treating sleep issues |
| JP2022538170A (ja) * | 2019-06-26 | 2022-08-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 睡眠問題の治療のためのレンボレキサント |
| KR20220061950A (ko) | 2019-09-13 | 2022-05-13 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 불면증을 치료하기 위한 약제학적 조성물 |
| WO2021048822A1 (en) * | 2019-09-13 | 2021-03-18 | Takeda Pharmaceutical Company Limited | Tak-925 for use in treating narcolepsy |
| EP4076463A1 (en) * | 2019-12-20 | 2022-10-26 | Eisai R&D Management Co., Ltd. | Use of lemborexant for treating insomnia |
| IL328515A (en) | 2020-01-16 | 2026-07-01 | Eisai R&D Man Co Ltd | Lamborxant drug substance and medical preparation containing it |
| MX2022011179A (es) | 2020-04-19 | 2022-10-07 | Idorsia Pharmaceuticals Ltd | Uso medico de daridorexant. |
| CN111450076A (zh) * | 2020-05-25 | 2020-07-28 | 安徽省逸欣铭医药科技有限公司 | 一种Lemborexant软胶囊组合物及其制备方法 |
| CN120076808A (zh) | 2022-09-23 | 2025-05-30 | 卫材R&D管理有限公司 | 减少与神经退行性疾病相关的神经退行性变的方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06328057A (ja) | 1993-05-26 | 1994-11-29 | Sanyo Electric Co Ltd | 厨芥処理装置 |
| EP0828751A4 (en) | 1995-05-05 | 1999-01-20 | Human Genome Sciences Inc | HUMAN NEUROPEPTIDE RECEPTOR |
| US6001963A (en) | 1996-12-17 | 1999-12-14 | Smithkline Beecham Corporation | Ligands of the neuropeptide receptor HFGAN72 |
| US6309854B1 (en) | 1996-12-17 | 2001-10-30 | Smithkline Beecham Corporation | Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72 |
| US6020157A (en) | 1997-04-30 | 2000-02-01 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72X receptor |
| US5935814A (en) | 1997-04-30 | 1999-08-10 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72Y receptor |
| US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
| RU2378257C2 (ru) | 2004-03-01 | 2010-01-10 | Актелион Фармасьютиклз Лтд | Замещенные производные 1,2,3,4-тетрагидроизохинолина |
| WO2006033005A2 (en) | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Thrombopoietin receptor agonists |
| JP2006328057A (ja) | 2005-04-25 | 2006-12-07 | Eisai R & D Management Co Ltd | 抗不安薬及びそのスクリーニング方法 |
| EA015256B1 (ru) | 2006-03-15 | 2011-06-30 | Актелион Фармасьютикалз Лтд. | Производные тетрагидроизохинолина для повышения функции памяти |
| WO2007129188A1 (en) | 2006-05-10 | 2007-11-15 | Pfizer Japan Inc. | Cyclopropanecarboxamide compound |
| CA2662538A1 (en) | 2006-09-11 | 2008-03-20 | Glaxo Group Limited | Azabicyclic compounds as inhibitors of monoamines reuptake |
| CL2007002809A1 (es) | 2006-09-29 | 2008-04-18 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| AR064561A1 (es) | 2006-12-28 | 2009-04-08 | Actelion Pharmaceuticals Ltd | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. |
| MX2010002419A (es) | 2007-09-21 | 2010-03-30 | Sanofi Aventis | (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento. |
| PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
| CN102742210B (zh) * | 2010-02-15 | 2015-11-25 | 皇家飞利浦电子股份有限公司 | 用于减轻控制信道干扰的装置和方法 |
| RU2571414C2 (ru) * | 2010-09-22 | 2015-12-20 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Циклопропановые соединения |
| US20120165339A1 (en) | 2010-12-22 | 2012-06-28 | Eisai R&D Management Co., Ltd. | Cyclopropane derivatives |
| JP6659681B2 (ja) | 2014-10-23 | 2020-03-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 不眠症を治療するための組成物および方法 |
-
2015
- 2015-10-21 JP JP2017522213A patent/JP6659681B2/ja active Active
- 2015-10-21 KR KR1020177009858A patent/KR102444608B1/ko active Active
- 2015-10-21 CA CA2964504A patent/CA2964504C/en active Active
- 2015-10-21 SG SG11201703064WA patent/SG11201703064WA/en unknown
- 2015-10-21 ES ES15851934T patent/ES2843952T3/es active Active
- 2015-10-21 EP EP15851934.8A patent/EP3209298B1/en active Active
- 2015-10-21 CN CN201580055472.XA patent/CN107810006B/zh active Active
- 2015-10-21 MX MX2017004950A patent/MX376164B/es active IP Right Grant
- 2015-10-21 WO PCT/JP2015/080304 patent/WO2016063995A1/en not_active Ceased
- 2015-10-21 US US15/519,676 patent/US10188652B2/en active Active
- 2015-10-21 BR BR112017007063-4A patent/BR112017007063A2/pt not_active Application Discontinuation
- 2015-10-21 RU RU2017112308A patent/RU2703297C2/ru active
- 2015-10-21 AU AU2015336463A patent/AU2015336463B2/en active Active
- 2015-10-21 SG SG10202007759RA patent/SG10202007759RA/en unknown
-
2017
- 2017-04-18 IL IL251759A patent/IL251759B/en active IP Right Grant
-
2019
- 2019-01-23 US US16/255,116 patent/US10702529B2/en active Active
-
2020
- 2020-03-16 US US16/819,341 patent/US11026944B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2964504C (en) | 2022-08-23 |
| IL251759A0 (en) | 2017-06-29 |
| US10702529B2 (en) | 2020-07-07 |
| EP3209298A1 (en) | 2017-08-30 |
| RU2703297C2 (ru) | 2019-10-16 |
| JP2017531683A (ja) | 2017-10-26 |
| AU2015336463B2 (en) | 2020-06-18 |
| US20200268754A1 (en) | 2020-08-27 |
| BR112017007063A2 (pt) | 2018-02-14 |
| JP6659681B2 (ja) | 2020-03-04 |
| WO2016063995A1 (en) | 2016-04-28 |
| SG11201703064WA (en) | 2017-05-30 |
| US20190201399A1 (en) | 2019-07-04 |
| RU2017112308A3 (enExample) | 2019-05-08 |
| SG10202007759RA (en) | 2020-09-29 |
| KR102444608B1 (ko) | 2022-09-20 |
| US20170252342A1 (en) | 2017-09-07 |
| KR20170068478A (ko) | 2017-06-19 |
| CA2964504A1 (en) | 2016-04-28 |
| AU2015336463A1 (en) | 2017-05-04 |
| MX376164B (es) | 2025-03-07 |
| EP3209298A4 (en) | 2018-06-20 |
| CN107810006A (zh) | 2018-03-16 |
| US11026944B2 (en) | 2021-06-08 |
| CN107810006B (zh) | 2021-03-30 |
| IL251759B (en) | 2021-01-31 |
| RU2017112308A (ru) | 2018-11-26 |
| MX2017004950A (es) | 2018-01-16 |
| EP3209298B1 (en) | 2020-12-02 |
| US10188652B2 (en) | 2019-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11026944B2 (en) | Compositions and methods for treating insomnia | |
| ES2706407T3 (es) | Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona | |
| ES2370409T3 (es) | Forma de dosificación que contiene oxicodona y naloxona. | |
| BR112019025286A2 (pt) | Métodos e composições para tratamento de sonolência excessiva | |
| PT2168585E (pt) | Composições farmacêuticas de um esteróide neuroactivo e as suas utilizações | |
| US20210128495A1 (en) | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine | |
| CN109640998A (zh) | 治疗昼夜节律性睡眠障碍的方法 | |
| JP2017531683A5 (enExample) | ||
| US11779563B2 (en) | Oral cannabinoid pharmaceutical compositions and methods of treating sleep disorders | |
| CN118267382A (zh) | 用于痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗 | |
| EP4727525A1 (en) | Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) | |
| WO2020249607A1 (en) | [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for treatment of chronic cough | |
| WO2020264201A1 (en) | Lemborexant for treating sleep issues | |
| JP6738797B2 (ja) | レット症候群治療薬 | |
| CN117769423A (zh) | 莱博雷生用于在治疗与神经系统变性疾病相关的不规律睡眠觉醒节律紊乱和昼夜节律性睡眠障碍的方法中使用 | |
| EP3989976A1 (en) | Lemborexant for treating sleep issues | |
| WO2020263331A1 (en) | Lemborexant for treating sleep issues |